Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tabalumab + bortezomib
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
**Tabalumab + bortezomib** is an investigational drug combination targeting relapsed or refractory multiple myeloma. It combines tabalumab (LY2127399), a fully human anti-BAFF monoclonal antibody, with bortezomib, a proteasome inhibitor. Tabalumab inhibits B-cell activating factor (BAFF), a cytokine crucial for B-cell survival and implicated in the growth and resistance of multiple myeloma cells. Bortezomib blocks the proteasome-mediated degradation of proteins, triggering apoptosis in plasma cells. Preclinical and clinical studies suggest this combination may help overcome BAFF-related resistance and improve myeloma control by acting on both tumor cell survival and bone disease[1][3][5].
- Brand names
- tabalumab
- Other names
- LY2127399 + bortezomibtabalumab + bortezomib
02
Targets
26S proteasomeBAFF (Tumor necrosis factor ligand superfamily member 13B)
Beyond the preview
Go deeper on tabalumab + bortezomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tabalumab + bortezomib.